The March 13, 2025, meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee on the influenza vaccine strains for the 2025-2026 influenza season in the U.S. has been cancelled. FDA continues to work with federal and international partners and U.S.-licensed influenza vaccine manufacturers to prepare for the upcoming season. FDA, in consultation with our federal partners, will review the available data to make our recommendations to manufacturers of U.S.-licensed influenza vaccines in time for the production of updated vaccines for the 2025-2026 influenza season. We do not anticipate any impact on vaccine supply or timing of availability.
FDA Plans for Selecting Influenza Virus Strains for Vaccine Composition for the 2025-2026 U.S. Influenza Season
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
